Development and internal–external cross-validation of a patient-reported definition for acute calcium pyrophosphate crystal arthritis
Open Access
- 14 December 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 2609-2617
Abstract
Objective: To develop and validate a patient-reported definition of acute calcium pyrophosphate (CPP) crystal arthritis in people with crystal-proven CPP deposition (CPPD) disease. Methods: Consecutive patients with crystal-proven CPPD disease from seven centres across four countries were enrolled in a cross-sectional study. In each centre, patient-reported outcomes on the features of acute CPP crystal arthritis were collected. The expert opinion of an independent rheumatologist was the reference standard. We developed definitions based on multivariable logistic regression model with backward selection of predictors and classification and regression tree (CART) approaches. Results: Two hundred and forty-six patients [mean age 73.2 years (s.d. 10.7), 65.9% female] were enrolled. At the time of the assessment, acute CPP crystal arthritis was diagnosed in 96/246 (39.0%) participants. Patient-reported joint warmth, patient-reported joint swelling, time from pain onset to peak, and self-reported acute CPP crystal inflammatory arthritis were included in the multivariable logistic model. This model had good discrimination (optimism-adjusted c-index: 0.92; 95% CI: 0.89, 0.95) and calibration (optimism-adjusted calibration slope: 0.95; 95% CI: 0.71, 1.19; optimism-adjusted calibration-in-the-large: 0.005; 95% CI: −0.37, 0.37) in the internal validation. Probability threshold ≥0.53 had sensitivity of 0.83 (95% CI: 0.74, 0.90) and specificity of 0.86 (95% CI: 0.79, 0.91). Performances were similar in the internal–external cross-validation. The CART identified patient-reported acute CPP crystal inflammatory arthritis, followed by joint swelling and joint warmth as the most informative variables for ascertaining acute CPP crystal arthritis [sensitivity 0.83 (95% CI: 0.72, 0.91) and specificity 0.83 (95% CI: 0.74, 0.90)]. Conclusion: We developed and initially validated easy-to-use patient-reported definitions for acute CPP crystal arthritis for use in clinical trials and observational research in CPPD.Keywords
This publication has 30 references indexed in Scilit:
- Features Associated With Different Inflammatory Phenotypes of Calcium Pyrophosphate Deposition Disease: A Study Using Data From the International American College of Rheumatology/EULAR Calcium Pyrophosphate Deposition Classification Criteria CohortArthritis & Rheumatology, 2024
- The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition DiseaseArthritis & Rheumatology, 2023
- Imaging Features of Calcium Pyrophosphate Deposition Disease: Consensus Definitions From an International Multidisciplinary Working GroupArthritis Care & Research, 2022
- 2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu ArteritisArthritis & Rheumatology, 2022
- Review: Outcome measures in calcium pyrophosphate depositionBest Practice & Research Clinical Rheumatology, 2021
- 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus ErythematosusArthritis & Rheumatology, 2019
- Developing a provisional definition of flare in patients with established goutArthritis & Rheumatism, 2011
- Classification criteria for psoriatic arthritis: Development of new criteria from a large international studyArthritis & Rheumatism, 2006
- Development and validation of the health assessment questionnaire II: A revised version of the health assessment questionnaireArthritis & Rheumatism, 2004
- Intravenous colchicine in the treatment of acute pseudogoutArthritis & Rheumatism, 1980